Lysosomal storage disorders: old diseases, present and future challenges.

Area of Science:

• Biochemistry
• Genetics
• Pediatrics

Background:

• Lysosomal storage diseases (LSDs) are a group of approximately 50 inherited metabolic disorders.
• They occur in about 1 in 7000 newborns and are caused by deficiencies in lysosomal enzymes or transporters.
• This leads to the accumulation of undegraded metabolites within lysosomes, causing cellular dysfunction and pathology.

Purpose of the Study:

• To review the historical discoveries in lysosomal storage disease (LSD) biology.
• To explore the progression from initial phenotype descriptions to current understanding of molecular bases.
• To discuss animal models, therapeutic strategies, and treatment challenges for LSDs.

Main Methods:

• Literature review of historical scientific publications.
• Analysis of research on genetic and molecular bases of LSDs.
• Synthesis of information on animal models and therapeutic approaches.

Main Results:

• LSDs were first described in the 1880s, with significant advancements in understanding their genetic and molecular underpinnings over the past century.
• Despite extensive research, the precise mechanisms linking intra-lysosomal accumulation to specific cell dysfunction and pathology remain incompletely understood.
• Various therapeutic strategies have been developed, but significant challenges persist in treating this diverse group of diseases.

Conclusions:

• Lysosomal storage diseases represent a significant challenge in inherited metabolic disorders, requiring continued research into underlying mechanisms.
• Understanding the historical progression of LSD research is crucial for developing effective and targeted therapies.
• Future efforts must focus on bridging the knowledge gap between metabolite accumulation and disease pathology to improve treatment outcomes.